



Health Research Authority

North West - Greater Manchester South Research Ethics Committee

3rd Floor, Barlow House
4 Minshull Street
Manchester
M1 3DZ

Please note: This is the favourable opinion of the REC only and does not allow you to start your study at NHS sites in England until you receive HRA Approval.

27 May 2020

Dr Tim England
Clinical Associate Professor in Stroke Medicine
University of Nottingham
Vascular Medicine, Division of Medical Sciences & GEM,
The Medical School, Royal Derby Hospital, Uttoxeter Rd,
Derby
DE22 3NE

Dear Dr England,

Study title:	Remote Ischaemic Conditioning After Stroke 3 (RECAST-3): A multicentre randomised controlled trial
REC reference:	20/NW/0173
Protocol number:	20011
IRAS project ID:	277021

Thank you for your letter of 07 May 2020, responding to the Committee's request for further information on the above research and submitting revised documentation.

The further information has been considered on behalf of the Committee by the Chair.

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation as revised,

subject to the conditions specified below.

Mental Capacity Act 2005 (England and Wales)

Mental Capacity Act (Northern Ireland) 2016

Conditions of the favourable opinion

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS management permission (in Scotland) should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).

Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for research is available in the Integrated Research Application System.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations

Registration of Clinical Trials

It is a condition of the REC favourable opinion that **all clinical trials are registered** on a publicly accessible database. For this purpose, 'clinical trials' are defined as the first four project categories in IRAS project filter question 2. Registration is a legal requirement for clinical trials of investigational medicinal products (CTIMPs), except for phase I trials in healthy volunteers (these must still register as a condition of the REC favourable opinion).

Registration should take place as early as possible and within six weeks of recruiting the first research participant at the latest. Failure to register is a breach of these approval conditions, unless a deferral has been agreed by or on behalf of the Research Ethics Committee (see here for more information on requesting a deferral: <https://www.hra.nhs.uk/planning-and-improving-research/research-planning/research-registration-research-project-identifiers/>

As set out in the UK Policy Framework, research sponsors are responsible for making information about research publicly available before it starts e.g. by registering the research project on a publicly accessible register. Further guidance on registration is available at: <https://www.hra.nhs.uk/planning-and-improving-research/research-planning/transparency-responsibilities/>

You should notify the REC of the registration details. We will audit these as part of the annual progress reporting process.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

After ethical review: Reporting requirements

The attached document “After ethical review – guidance for researchers” gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study, including early termination of the study
- Final report

The latest guidance on these topics can be found at <https://www.hra.nhs.uk/approvals-amendments/managing-your-approval/>.

Ethical review of research sites

NHS/HSC sites

The favourable opinion applies to all NHS/HSC sites listed in the application subject to confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or management permission (in Scotland) being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion" below).

Non-NHS/HSC sites

I am pleased to confirm that the favourable opinion applies to any non-NHS/HSC sites listed in the application, subject to site management permission being obtained prior to the start of the study at the site.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

<i>Document</i>	<i>Version</i>	<i>Date</i>
Covering letter on headed paper [Cover letter]		10 March 2020
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Insurance]		30 July 2019
GP/consultant information sheets or letters [GP letter]	1.0	29 January 2020
Instructions for use of medical device [Technical Dossier]	1.0	29 January 2020
IRAS Application Form [IRAS_Form_11032020]		11 March 2020
Letter from funder [Funder letter]		06 November 2019
Letter from sponsor [Sponsor letter]		10 March 2020
MHRA Notice of No Objection Letter (Medical Devices) and relevant correspondence [Notice of No objection letter]		10 March 2020
Other [Delegation log]	1.0	
Other [Medico-technical test]	1.0	15 January 2018
Other [Provisional response letter responses]		
Other [NIHR funding contract]		
Other [Updated protocol]	1.1	29 April 2020
Other [Consultee consent]	1.1	29 April 2020
Other [Consent form]	1.1	29 April 2020
Other [MRI consent form]	1.1	29 April 2020
Other [PIS re-consent]	1.1	29 April 2020
Other [PIS]	1.1	29 April 2020
Other [Consultee PIS]	1.1	29 April 2020
Referee's report or other scientific critique report [CE certificate]		02 October 2017
Summary CV for Chief Investigator (CI) [CI CV]		21 December 2019

Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: <http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/>

HRA Learning



Health Research Authority

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities– see details at: <https://www.hra.nhs.uk/planning-and-improving-research/learning/>

IRAS project ID: 277021 Please quote this number on all correspondence
--

With the Committee's best wishes for the success of this project.

Yours sincerely,

P.P.
Professor Sobhan Vinjamuri
Chair

Email: gmsouth.rec@hra.nhs.uk

Enclosures: "After ethical review – guidance for
researchers"

Copy to: Ms Angela Shone